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Abstract
Cervical cancer screening is the key to reducing the incidence and mortality of cervical cancer in developing countries. In 
the absence of a national screening program, healthcare givers in Nigeria are encouraged to routinely inform and screen 
eligible women. This review aims at equipping health workers for this task by re-educating them on the basics of the 
disease and its screening by cytology. Relevant texts and online databases including Pubmed, African Journal Online, 
and Google Scholar, were searched for relevant literature on the subject area. Persistent infection by a high-risk human 
papilloma virus, especially types 16 and 18, is necessary for the development of cervical cancer. The exfoliation of cells 
from the metaplastic squamous cells of transformation zone of the cervix is the basis of cervical cytology. Organized Pap 
screening reduces the incidence and mortality of cervical cancer, but screening protocols vary. Nevertheless, annual 
screening is not recommended except for high-risk women such as HIV-positive women. Abnormal Pap smear results 
are currently reported using either the Bethesda System or the British Society for Clinical Cytology classification, and 
colposcopy with or without biopsy are necessary when indicated. In conclusion, the use of cervical cytology to detect pre-
cancerous lesions followed by an appropriate treatment when necessary is the key to reducing invasive cervical cancer. 
The task of provider-initiated counseling and testing for cervical cancer by health practitioners requires update on the 
current etio-pathology of cervical cancer, and its screening as reviewed.
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Introduction
Cervical cancer is a preventable cancer of the female 
genital tract. It is still a leading cause of cancer death 
among women in areas where organized screening is not 
available.[1] The disease is caused by infection with persistent 
oncogenic human papilloma virus (HPV), which makes 
timely vaccination with HPV vaccine an effective primary 
prevention method. However, the cost of the vaccine makes 
it inaccessible in developing countries, thereby leaving 
secondary prevention through cervical cytology as the best 
alternative method of cervical cancer prevention; this is 
without prejudice to the cheaper visual screening methods 
[using acetic acid (VIA) or Lugol’s iodine (VILI)], currently 
being advocated for poor-resource settings. VIA and VILI 
involve the inspection of the cervix without magnification, 
after painting with dilute acetic acid or Lugol’s iodine 
respectively; abnormal cervical tissue turns white (VIA) 
or yellow (VILI).
Furthermore, an important strategy towards reduction of the 
incidence and mortality of cervical cancer is by increasing 
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the screening rate of women that have not screened or 
those that screen infrequently.[2] Nevertheless, knowledge 
of the physio-anatomical changes of the cervix by health 
practitioners involved in reproductive health of women is 
very relevant, irrespective of the screening method being 
advocated. Because healthcare providers are encouraged to 
routinely inform and screen all eligible women for cervical 
cancer,[3] it becomes important to re-educate them on the 
basics of cervical neoplasm and cervical cytology. This review 
provides a concise discussion on the physiological changes 
in the cervical epithelium; association between HPV and 
cervical cancer; history, guidelines and reliability of Pap smear; 
and the classification of abnormal cervical cytology.
Materials and Methods
Literature search was both manual and electronic. Relevant 
texts were searched for information on the subject area. 
Online databases including Pubmed, African Journal 
Online, and Google Scholar were also searched using a 
combination of the key words. Related literatures were 
identified and studied, and relevant information retrieved. 
The information was further organized and presented in 
themes.
Cervical squamo-columnar junction
The cervix is the inferior one-third of the adult uterus and 
consists of the endocervix and ecto-cervix [Figure 1]. The 
latter projects and opens into the vagina, thereby making 
it accessible for inspection and sampling. Furthermore, the 
cervical canal is lined by columnar epithelium superiorly 
and squamous epithelium inferiorly – both epithelia meet 
at a dynamic point referred to as the squamo-columnar 
junction [point A in Figure 1]. The original squamo-
columnar junction (SCJ) is the boundary between the 
original squamous epithelium covering the ectocervix and 
the columnar epithelium of the endocervix.[4] The position 
of this junction varies throughout the reproductive life of 
a woman [Figure 1]. In an estrogen-deficient state such as 
in pre-pubertal women, the junction lies well within the 
endocervical canal. During puberty, there is down-growth 
of the columnar epithelium below the external cervical os; 
thus, the SCJ lies on the ectocervix. However, this delicate 
columnar epithelium exposed to the lactobacilli-created 
acid environment of the vagina undergoes metaplasia to 
become squamous epithelium. As squamous metaplasia 
takes place, the original SCJ becomes the border between 
the metaplastic squamous epithelium and the original 
squamous epithelium [point A in Figure 1]. The superior 
border of the metaplastic epithelium becomes the new 
squamo-columnar junction (NSCJ) [point B in Figure 1]. 
The area between the original SCJ and the NSCJ of the 
cervix [i.e., in-between points A and B in Figure 1], where 
this continuous epithelial regeneration and remodeling take 
place is known as the transformation zone (TZ).[4,5]
The process of metaplasia can be disrupted, leading to 
disordered squamous epithelium. The metaplastic squamous 
epithelium in the TZ is the critical site for the development 
of the cervical neoplasia. Exfoliation of cells from this zone 
is the basis for cervical cytology.[6]
Human papilloma virus and cervical neoplasia
HPV is the name of a group of epitheliotrophic DNA viruses 
that includes more than 100 different strains or subtypes 
involved in human disease. They are numbered according 
to their discovery. About 30 of these are sexually transmitted 
and are primarily transmitted to the genital tract through 
skin-to-skin contact.[7] On the basis of both epidemiologic 
and phylogenetic classification, the 30 genital HPV types are 
classified into high-risk (16, 18, 31, 33, 35, 39, 45, 51, 52, 
56, 58, 59, 68, 73, and 82), possibly high-risk (26, 53, and 
66), and low risk (6, 11, 40, 42, 43, 44, 54, 61, 70, 72, 81, 
and CP6108). [8] They infect the basal cells of the stratified 
squamous epithelium as well as the metaplastic cells of 
the transformation zone of the cervix. Depending on the 
HPV genotype and the host/virus interaction, there can be 
asymptomatic infection, clinical manifestations of genital 
warts, or cervical dysplastic changes.[9] The low-risk HPV types 
are associated with condylomas, which are benign lesions, 
while the high-risk types have been solidly demonstrated as 
the cause of the cervical cancer and its immediate precursors 
(severe dysplasia and carcinoma in situ).[10-12] HPVs are 
found in over 85%–90% of all precancerous and invasive 
cervical lesions, and most of the behavioral and sexual risk 
factors for cervical cancer become statistically insignificant as 
independent variables after adjusting for HPV infection.[9] The 
most frequent types detected, in decreasing order of frequency, 
were 16, 18, 45, 31, 33, 52, 58, and 35.[9] However, HPV 16 
and 18 are responsible for 70% of cervical cancers, with trivial 
differences among countries, and for over 60% of cervical 
intraepithelial neoplasia (CIN) 2/3 lesions worldwide. [13,14] This 
may explain why the HPV vaccines in current use contain 
antigens for both HPV 16 and 18.
Figure 1: The human cervix at different reproductive periods[4]
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HPV infection can be transient or persistent. It is persistent 
when the presence of the viral DNA can be assessed by 
polymerase chain reaction after six months’ interval. [15] 
Persistence of oncogenic HPV viruses is required for 
the cellular changes associated with cervical dysplasia; 
however, most HPV infections are unnoticed and resolve 
spontaneously within 24 months.[9] Persistent HPV 
infection plays the causal role in the development of 
cervical cancer and its precursors by integrating into the 
host’s cellular genome and interfering with the essential 
regulatory mechanism of cellular growth, DNA repair, 
and immunological escape, thus permitting uncontrolled 
cellular proliferation.[11,16] A cell-mediated immune response 
is required for HPV containment and lesion regression; 
therefore, people with cell-mediated immune dysfunction 
such as HIV/AIDS have higher rates of HPV infection and 
are more likely to manifest large, multifocal, and dysplastic 
lesions.[9] Furthermore, cigarette smoking among HIV-
infected women significantly increases the prevalence and 
incidence of HPV infection, alters the natural history of 
the infection (HPV), as well as increases the risk of cervical 
disease.[17]
Papanicolaou (Pap) smear
The fact that cervical cancer develops slowly from its 
precursor lesions makes it a suitable disease for screening.[5] 
The Pap test is a complex system of laboratory and clinical 
procedures, which has been widely used globally in the 
diagnosis of pre-malignant lesions and cancer of the cervix.[6] 
It is a secondary prevention method, aimed at identifying the 
precancerous lesions that need follow-up and/or treatment. [9] 
It was named after George N. Papanicolaou who first 
discovered that cervical cancer cells might be observed in 
human vaginal smears made from exfoliated cells collected 
from the posterior fornix of vagina. [6] Afterwards, in 1947, 
a Canadian gynecologist, Ernest J. Ayre, documented an 
easier and more efficient method of using a wooden spatula 
to obtain smears directly from the cervix.[18] The sample for 
Pap test should contain cells from the squamous epithelium 
of vaginal portion of the cervix, the transformation zone, and 
the endocervix. To obtain a better sample from the latter, 
Ayre spatula was modified into extended tip spatulas such as 
Aylesbury; cytobrush and other endocervical brushes were 
also introduced – their shapes enable them to be inserted 
deeper into the endocervix.[6,19,20] The cytobrush should not 
be used alone, and when combined with the conventional 
Ayre spatula, the number of inadequate smears is reduced 
and hence the false negative rate.[19,21,22] Fine cotton wool 
stick can also be used to collect endocervical cell samples 
but the results are less satisfactory.[6,22] The Pap test requires 
fixing of the cervical scraping on a glass slide followed by 
staining with Papanicolaou staining and manual analysis 
under the microscope.
It is well recognized that Pap test reduces the incidence 
and mortality of cervical cancer.[23] It diminishes the risk of 
progression of a precancerous lesion to cancer, and should 
only be carried out in asymptomatic women.[9] The level 
of protection for women aged 35–64 years is about 93.5% 
for annual screening, 83.5% for screening every 5 years, 
and 64% for screening every 10 years.[24] Furthermore, it 
is estimated that organized screening can reduce cervical 
cancer deaths by 70% or more, prevent not only the loss of 
large numbers of life years but also the morbidity and costs 
of treating advanced disease, and in many cases, preserve 
fertility when it might otherwise be lost.[9] Nevertheless, 
there has not been a universal agreement as to the age at 
initiation or cessation of Pap smear as well as the intervals 
for repeat screening.[25] The World Health Organization 
(WHO) recommended a 5-year screening interval for 
women over 50 years and a 3-year interval for those within 
the age group of 25–49 years if the resources are available.[26] 
It did not recommend annual screening at any age; and for 
women above 65 years, screening is not necessary provided 
the last two previous smears were negative. Though, the 
WHO recommended that organized cervical cytology 
programs should not include women less than 25 years of 
age in their target populations, the American College of 
Obstetricians and Gynecologists (ACOG) protocol indicates 
that cervical cytology should begin for every woman by 
age 21 years, irrespective of HPV vaccination status.[2] 
Afterwards, she should continue with 2-yearly screening 
until the age of 29 years. From the age of 30 years, screening 
interval could be increased to 3 years for women who had 
three consecutive negative cervical cytology tests. However, 
cervical cancer screening should stop at age 65 or 70 years 
among women who have three or more negative cytology 
results in a row and no abnormal test results in the past. 
With respect to cost analysis, it has been shown that the 
3-yearly cervical cytology screening is the most cost-effective 
strategy for women with prior normal results.[27]
On the other hand, high-risk women such as the HIV-
positive, immunosuppressed, and those exposed to 
diethylstilbestrol, should be screened more frequently.[2] For 
HIV-positive women in particular, twice yearly Pap smear 
is recommended in the first year after diagnosis, and if the 
results are normal, screening should continue annually 
afterwards.[28]
Pap test is generally very specific (86%–100%) but has varied 
sensitivity of 30%–80%.[29] It has an apparently high false 
negative rate of up to 50% for invasive carcinoma and 28% 
for pre-invasive lesions,[30] which are contributed mainly by 
sampling error and screening error.[31] Other causes of error 
include interpretative error and exfoliative potential of the 
lesion; for instance, false negative smear have been reported 
in as many as 40%–50% of patients with invasive cervical 
cancer, which emphasizes that it is a screening procedure 
for detecting precursor lesions and not a diagnostic method 
for cervical cancer.[5] Though serial Pap testing improves 
sensitivity, and diminishes impact of false negativity,[9] newer 
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automated techniques have been developed to supplement 
manual screening and further improve accuracy. These 
techniques are the Pap-net system and the thin-prep system. 
The former is a computer-assisted slide reader used for 
re-screening the manually diagnosed negative smears. [32] 
The thin-prep system is a liquid-based alternative to the 
conventional slide Pap smear preparation, where the 
collection device is rinsed in a tube of preservative solution 
and sent to the laboratory. The specimen is centrifuged with 
removal of blood and mucus. Afterwards, the cellular pellet 
is then removed and suspended in a diluent and a smear is 
then made on the slide. These new techniques, although 
effective,[33] increase the cost of screening. Therefore, since 
false negative smears contribute only a small fraction to 
the incidence of cervical carcinoma, resources, especially 
in resource poor countries, should be spent to increase the 
screening of the population by conventional Pap smear.[21]
Most importantly, despite the recognized importance of 
regular Pap smear, it cannot be effective if the people who 
need it, especially women at high risk, are neither aware 
of it nor convinced that they need it.[6] Unfortunately, the 
awareness of cervical cytology by women alone might not 
translate to its increased use, therefore, the need for an 
additional motivation for women.[3]
Furthermore, in addition to the prevailing low awareness of 
cervical cancer and Pap test among the women population 
as well as lack of priority on the disease prevention by policy 
makers, other impediments to the uptake of the cervical 
cytology include poor health consciousness, inadequate 
spread of health centers with Pap screening facilities, poor 
referral system, and lack of a national screening program.[34,35]
Classification of abnormal cervical cytology
The oldest classification is the Papanicolaou classification, 
which classified smears into classes I to V in order of 
worsening cellular atypia. It is no longer favored because it 
does not reflect the current understanding of CIN and there 
is no equivalent in diagnostic histopathological terminology.[6]
In 1969, the World Health Organization proposed the term 
dysplasia, graded as mild, moderate, and severe, and the 
term carcinoma in situ to denote the pre-invasive lesions 
of cervix.[36] These terms are widely used all over the world 
for both cytological and histological diagnosis. However, 
there are no internationally agreed criteria for the grading.[6]
Currently, there are two systems in use for cytology reporting, 
one is from the British Society for Clinical Cytology,[37] and 
the other from the United States (The Bethesda System).[38]
Bethesda classification
In 1998, the National Cancer Institute (NCI) workshop 
held in Bethesda, Maryland, resulted in the development 
of the Bethesda system for cytological reporting. This was 
later revised to give the Bethesda system 2001.[38] This 
classification has a wider use, which may be related to the 
fact that it provides a uniform and well-defined diagnostic 
terminology that facilitates unambiguous communication 
between the laboratory and the clinician.[39]
The revised system divided the premalignant squamous 
lesions into three categories thus:[38]
i. Atypical squamous intraepithelial cells (ASC)
ii. Low-grade squamous intraepithelial lesions (LGSIL)
iii. High-grade squamous intraepithelial lesions (HGSIL)
The ASC is categorized into those of undetermined 
significance (ASC-US) and those in which a high-grade 
lesion cannot be excluded (ASC-H). In ASC-US, the 
squamous cells do not look completely normal but the 
meaning of the cell changes is not certain. In ASC-H also, 
the cells appear abnormal but the meaning is uncertain; 
however, the risk of being precancerous lesion is higher than 
ASC-US. LGSIL includes cytological changes consistent 
with HPV changes called koilocytic atypia or mild dysplasia, 
and it corresponds to CIN I. On the other hand, the HGSIL 
is characterized by more severe abnormalities in the size 
and shape of cervical squamous cells and are more likely 
to progress to cancer. It denotes the cytological findings 
corresponding to CIN II and CIN III [Table 1].
The British society for clinical cytology classification
Abnormal cytology is classified into mild, moderate, and 
severe dyskaryosis, and are equivalent to histological 
diagnosis of CIN I (mild dysplasia), CIN II (moderate 
dysplasia), and CIN III (severe dysplasia) respectively. 
Mild dyskaryosis is equivalent to LGSIL while moderate 
and severe dyskaryosis correspond to HGSIL. The term 
borderline is taken to be equivalent to ASCUS [Table 1].
Cervical intraepithelial neoplasia
The CIN is a concept introduced in 1967 to embrace all 
grades of dysplasia and carcinoma in situ under a single 
disease heading.[40] The nomenclature conveys accurately 
the morphological unity and malignant potential of all 
cervical intraepithelial neoplastic lesions if left untreated. [6] 
It means the disordered growth and development of the 
epithelial of the cervix, and the diagnosis is based on 
histological sections. It is graded as I, II, and III, which 
are equivalent to the mild, moderate, and severe dysplasia 
respectively [Table 1]. The grading is based on the 
proportion of the epithelium occupied by the dysplastic cells. 
In CIN I, the disordered growth involves the lower third of 
the epithelial lining. Abnormal maturation of two-thirds 
of the cervical epithelium is called CIN II, while CIN III 
encompasses more than two-thirds of the epithelial lining.[14]
The epidemiological risk factors in CIN and cervical cancer 
include multiple sexual partners, early onset of sexual 
activity, HPV infection, lower genital tract neoplasia, history 
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of STDs, cigarette smoking, immunodeficiency, multiparity, 
and long-term oral contraceptive pill use.[14]
The need for appropriate interpretation of abnormal Pap 
result and appropriate referral of patients by health workers 
for optimal follow-up cannot be overemphasized. Generally, 
all women with ASC or LGSIL should have a repeat screening 
after 6 months and should be referred for colposcopy if the 
lesion is progressive [Table 1]. However, all cases of HGSIL 
should have colposcopy and possible biopsy.[21,41] On the other 
hand, abnormal lesion of any type identified in high-risk 
women, such as HIV-positive women, calls for colposcopy. [42] 
Unfortunately, high level of refusal of colposcopy has been 
reported from Southeastern Nigeria, and the major reasons 
were the fear of detecting cervical cancer and compromising 
future fertility.[43] It is likely that the situation for other 
regions of Nigeria and indeed sub-Saharan Africa, may not 
be different. This worrisome situation underscores the need 
for adequate provider initiated counseling on cervical cancer 
prior to any form of testing.
Conclusion
Cervical cytology is a key part of the secondary prevention of 
cervical cancer. In the absence of national guidelines in most 
developing countries, a provider initiated counseling and 
testing for cervical cancer is advocated.[3,44] This strategy will 
ensure that every eligible woman who presents to a healthcare 
provider for any reason is informed about and possibly screened 
for cervical cancer. Therefore, basic knowledge of the current 
etio-pathology of cervical cancer as well as its prevention is 
very essential for health practitioners in developing countries. 
It is hoped that their improved knowledge will motivate their 
involvement in the campaign against this preventable scourge 
of female reproductive health.
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